CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions.
B-cell maturation antigen
T-cell
chimeric antigen receptor
cytokine release syndrome
immunotherapy
multiple myeloma
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
06
03
2020
accepted:
16
06
2020
entrez:
28
8
2020
pubmed:
28
8
2020
medline:
28
8
2020
Statut:
epublish
Résumé
Despite recent therapeutic advances, the prognosis of multiple myeloma (MM) patients remains poor. Thus, new strategies to improve outcomes are imperative. Chimeric antigen receptor (CAR) T-cell therapy has changed the treatment landscape of B-cell malignancies, providing a potentially curative option for patients who are refractory to standard treatment. Long-term remissions achieved in patients with acute lymphoblastic leukemia and Non-Hodgkin Lymphoma encouraged its further development in MM. B-cell maturation antigen (BCMA)-targeted CAR T-cells have established outstanding results in heavily pre-treated patients. However, several other antigens such as SLAMF7 and CD44v6 are currently under investigation with promising results. Idecabtagene vicleucel is expected to be approved soon for clinical use. Unfortunately, relapses after CAR T-cell infusion have been reported. Hence, understanding the underlying mechanisms of resistance is essential to promote prevention strategies and to enhance CAR T-cell efficacy. In this review we provide an update of the most recent clinical and pre-clinical data and we elucidate both, the potential and the challenges of CAR T-cell therapy in the future.
Identifiants
pubmed: 32850376
doi: 10.3389/fonc.2020.01243
pmc: PMC7399644
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1243Informations de copyright
Copyright © 2020 Rodríguez-Lobato, Ganzetti, Fernández de Larrea, Hudecek, Einsele and Danhof.
Références
Clin Cancer Res. 2018 Jan 1;24(1):106-119
pubmed: 29061640
N Engl J Med. 2018 Feb 1;378(5):439-448
pubmed: 29385370
Blood. 2014 May 15;123(20):3128-38
pubmed: 24569262
Immunol Rev. 2011 Nov;244(1):115-33
pubmed: 22017435
Nat Med. 2015 Jun;21(6):581-90
pubmed: 25939063
J Immunol. 2011 Feb 1;186(3):1840-8
pubmed: 21187443
Blood. 2002 Sep 15;100(6):2175-86
pubmed: 12200383
Br J Haematol. 2012 Sep;158(6):727-38
pubmed: 22804669
J Exp Med. 2005 Oct 3;202(7):907-12
pubmed: 16203864
Int J Oncol. 2012 Sep;41(3):876-84
pubmed: 22766978
J Clin Invest. 2016 Jul 1;126(7):2588-96
pubmed: 27270177
J Clin Invest. 2008 Sep;118(9):3132-42
pubmed: 18688285
Blood. 2014 Jul 10;124(2):188-95
pubmed: 24876563
Haematologica. 2017 Apr;102(4):785-795
pubmed: 28034989
N Engl J Med. 2018 Feb 8;378(6):518-528
pubmed: 29231133
Nat Rev Drug Discov. 2020 Mar;19(3):185-199
pubmed: 31900462
Sci Transl Med. 2012 May 2;4(132):132ra53
pubmed: 22553251
Int Immunol. 1998 Nov;10(11):1693-702
pubmed: 9846698
Hemasphere. 2019 Mar 29;3(2):e186
pubmed: 31723825
Nat Commun. 2020 Feb 7;11(1):798
pubmed: 32034142
Matrix Biol. 2014 Apr;35:215-22
pubmed: 24145151
Mol Immunol. 2015 Oct;67(2 Pt A):89-94
pubmed: 25964097
Cancer Cell. 2019 Mar 18;35(3):473-488.e6
pubmed: 30889381
Cancer Discov. 2018 Oct;8(10):1219-1226
pubmed: 30135176
Mol Ther. 2009 Aug;17(8):1453-64
pubmed: 19384291
Front Immunol. 2016 Mar 30;7:112
pubmed: 27066005
Blood. 2017 Aug 3;130(5):606-618
pubmed: 28637663
Leukemia. 2021 Jan;35(1):201-214
pubmed: 32350373
Blood. 2008 Mar 1;111(5):2755-64
pubmed: 18180376
Biochem Biophys Res Commun. 1987 Dec 31;149(3):960-8
pubmed: 3122749
Blood. 2019 Apr 25;133(17):1876-1887
pubmed: 30782611
Blood. 2016 Jun 23;127(25):3225-36
pubmed: 27127303
Hematology. 2013 Nov;18(6):348-51
pubmed: 23510526
Blood. 2004 Jan 15;103(2):656-63
pubmed: 14563636
Blood. 2019 Nov 7;134(19):1585-1597
pubmed: 31558469
Blood Adv. 2019 Jul 9;3(13):2022-2034
pubmed: 31289029
Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6064-72
pubmed: 17062682
Nat Med. 2018 Jun;24(6):731-738
pubmed: 29808005
Leukemia. 2016 Feb;30(2):492-500
pubmed: 26369987
Nat Med. 2017 Dec;23(12):1436-1443
pubmed: 29106400
Cancer Res. 2008 Jan 1;68(1):190-7
pubmed: 18172311
Sci Transl Med. 2019 Jul 3;11(499):
pubmed: 31270272
Immunol Lett. 2011 Jan 30;134(2):129-36
pubmed: 20933013
Oncologist. 2018 Aug;23(8):943-947
pubmed: 29622697
Nat Biotechnol. 2018 Oct;36(9):847-856
pubmed: 30102295
Ann Hematol. 2017 Aug;96(8):1407-1410
pubmed: 28577043
Cancer Immunol Res. 2019 Jul;7(7):1047-1053
pubmed: 31113804
Nat Med. 2015 Aug;21(8):914-921
pubmed: 26193344
J Immunother Cancer. 2018 Jun 15;6(1):56
pubmed: 29907163
Biol Blood Marrow Transplant. 2010 Sep;16(9):1245-56
pubmed: 20304086
Blood. 2008 Aug 15;112(4):1329-37
pubmed: 17906076
Nat Rev Clin Oncol. 2018 Apr;15(4):218
pubmed: 29434335
N Engl J Med. 2016 Aug 25;375(8):754-66
pubmed: 27557302
Blood. 2016 Sep 29;128(13):1688-700
pubmed: 27412889
Biol Blood Marrow Transplant. 2019 Apr;25(4):e123-e127
pubmed: 30586620
Blood. 2017 Nov 23;130(21):2295-2306
pubmed: 28924019
Nat Rev Immunol. 2008 Dec;8(12):958-69
pubmed: 19029990
Clin Cancer Res. 2007 Oct 1;13(19):5903-9
pubmed: 17908986
Mol Ther. 2010 Apr;18(4):843-51
pubmed: 20179677
Hum Vaccin Immunother. 2015;11(7):1606-11
pubmed: 26001047
Nature. 2017 Mar 2;543(7643):113-117
pubmed: 28225754
Blood. 2004 Mar 15;103(6):2332-6
pubmed: 14630803
Nat Rev Dis Primers. 2017 Jul 20;3:17046
pubmed: 28726797
Cancer Res. 2015 Sep 15;75(18):3853-64
pubmed: 26183927
Leukemia. 2018 Feb;32(2):402-412
pubmed: 28951562
Nat Commun. 2020 Jan 15;11(1):283
pubmed: 31941907
Cold Spring Harb Perspect Biol. 2010 Mar;2(3):a002469
pubmed: 20300214
Clin Cancer Res. 2008 May 1;14(9):2775-84
pubmed: 18451245
JCI Insight. 2019 Feb 21;4(4):
pubmed: 30830874
Mol Cancer Ther. 2019 Dec;18(12):2246-2257
pubmed: 31395689
Blood. 2017 Jun 22;129(25):3386-3388
pubmed: 28476749
Blood. 2009 Jul 16;114(3):535-46
pubmed: 19451549
Int J Cancer. 2018 May 1;142(9):1738-1747
pubmed: 29119551
Nat Rev Clin Oncol. 2019 Jan;16(1):45-63
pubmed: 30082906
Leukemia. 2017 Jan;31(1):186-194
pubmed: 27491640
Blood. 2018 Feb 15;131(7):746-758
pubmed: 29284597
Blood Cancer Discov. 2020 Sep;1(2):146-154
pubmed: 33089218
Lancet. 2019 Jul 6;394(10192):29-38
pubmed: 31171419
Curr Opin Immunol. 2016 Apr;39:44-51
pubmed: 26796069
Hum Gene Ther. 2018 May;29(5):585-601
pubmed: 29641319
Oncoimmunology. 2016 Nov 8;5(12):e1253656
pubmed: 28180032
Blood. 2002 Aug 15;100(4):1113-22
pubmed: 12149187
Mol Ther Oncolytics. 2016 Apr 20;3:16011
pubmed: 27626062
Blood Adv. 2019 Oct 8;3(19):2812-2815
pubmed: 31575532
Sci Transl Med. 2019 Mar 27;11(485):
pubmed: 30918115
PLoS One. 2018 May 30;13(5):e0197349
pubmed: 29847570
Nature. 2018 Jun;558(7709):307-312
pubmed: 29849141
Lancet Haematol. 2019 Oct;6(10):e521-e529
pubmed: 31378662
Mol Ther. 2017 Aug 2;25(8):1946-1958
pubmed: 28506593
Eur J Clin Invest. 2012 Sep;42(9):953-60
pubmed: 22591013
Haematologica. 2005 Apr;90(4):489-93
pubmed: 15820944
Blood. 1990 Jul 15;76(2):377-82
pubmed: 1695113
J Exp Med. 2004 Jan 5;199(1):91-8
pubmed: 14707116
Blood. 2017 Dec 28;130(26):2838-2847
pubmed: 29089311
Cancer Immunol Res. 2015 Feb;3(2):125-35
pubmed: 25212991
N Engl J Med. 2019 May 30;380(22):2104-2115
pubmed: 31141632
Gene Ther. 2013 Apr;20(4):386-95
pubmed: 22739387
Mol Ther. 2013 Apr;21(4):904-12
pubmed: 23423337
Nat Commun. 2020 May 8;11(1):2283
pubmed: 32385241
J Clin Invest. 2019 Mar 21;129(6):2210-2221
pubmed: 30896447
Cancer Res. 2006 Jul 1;66(13):6675-82
pubmed: 16818641
Mol Ther. 2018 Jun 6;26(6):1447-1456
pubmed: 29678657
Cancer Immun. 2003 Jul 23;3:9
pubmed: 12875607
Haematologica. 2018 Mar;103(3):e126-e129
pubmed: 29191843
Clin Cancer Res. 2013 Apr 15;19(8):2048-60
pubmed: 23344265
Proc Natl Acad Sci U S A. 2019 May 7;116(19):9543-9551
pubmed: 30988175
N Engl J Med. 2015 Sep 10;373(11):1040-7
pubmed: 26352815
N Engl J Med. 2017 Dec 28;377(26):2545-2554
pubmed: 29226764
Mol Cell Biol. 2001 Jun;21(12):4067-74
pubmed: 11359913
Blood. 2004 Apr 15;103(8):3148-57
pubmed: 15070697
Cancer. 1977 Dec;40(6):2765-71
pubmed: 589554
Haematologica. 2019 Nov;104(11):2265-2273
pubmed: 30948492
Leuk Res. 2019 Jun;81:62-66
pubmed: 31035033
J Immunol. 2008 Mar 15;180(6):3655-9
pubmed: 18322170
Nat Commun. 2015 Jun 11;6:7333
pubmed: 26065893
Eur J Haematol. 2009 Aug;83(2):119-29
pubmed: 19456850
Nat Med. 2018 May;24(5):563-571
pubmed: 29713085
J Clin Oncol. 2018 Aug 1;36(22):2267-2280
pubmed: 29812997
BioDrugs. 2019 Jun;33(3):275-284
pubmed: 31069709
Eur J Haematol. 2020 Apr;104(4):318-327
pubmed: 31883150
Blood. 2014 Feb 27;123(9):1336-40
pubmed: 24385542
Haematologica. 2016 May;101(5):616-25
pubmed: 26858358
Front Immunol. 2018 Mar 21;9:507
pubmed: 29619024
Cancer Discov. 2018 Jun;8(6):750-763
pubmed: 29563103
J Clin Invest. 2003 Jul;112(2):286-97
pubmed: 12865416
Blood. 2004 Jan 15;103(2):689-94
pubmed: 14512299
Biol Blood Marrow Transplant. 2019 Apr;25(4):625-638
pubmed: 30592986
Cell Rep. 2017 Oct 3;21(1):17-26
pubmed: 28978471
Curr Opin Pharmacol. 2004 Aug;4(4):347-54
pubmed: 15251127
Annu Rev Immunol. 2003;21:231-64
pubmed: 12427767
N Engl J Med. 2019 May 2;380(18):1726-1737
pubmed: 31042825
Cancer Immunol Res. 2019 Jan;7(1):100-112
pubmed: 30396908
Gene Ther. 2010 May;17(5):678-86
pubmed: 20200563
Mol Cancer Ther. 2018 Sep;17(9):1795-1815
pubmed: 30181329
N Engl J Med. 2015 Aug 13;373(7):621-31
pubmed: 26035255
Nat Rev Clin Oncol. 2018 Jan;15(1):47-62
pubmed: 28925994
JCI Insight. 2017 Dec 7;2(23):
pubmed: 29212954
Clin Cancer Res. 2019 Dec 15;25(24):7506-7516
pubmed: 31548346
J Clin Oncol. 2018 Nov 10;36(32):3192-3202
pubmed: 30212291
Cancer Discov. 2017 Dec;7(12):1404-1419
pubmed: 29025771
Nature. 2017 Apr 27;544(7651):493-497
pubmed: 28424516
Nat Commun. 2019 Jul 17;10(1):3137
pubmed: 31316055
Blood. 2019 Apr 25;133(17):1799-1800
pubmed: 31023743
Proc Natl Acad Sci U S A. 1993 Jan 15;90(2):720-4
pubmed: 8421711
Front Immunol. 2018 Nov 05;9:2551
pubmed: 30455698
Hematol Oncol. 2019 Jun;37 Suppl 1:48-52
pubmed: 31187535
Leukemia. 2018 May;32(5):1157-1167
pubmed: 29479065
Medicine (Baltimore). 2019 Oct;98(43):e17572
pubmed: 31651858
Cancer Discov. 2018 Aug;8(8):958-971
pubmed: 29880584
Clin Lymphoma Myeloma Leuk. 2019 Jan;19(1):29-34
pubmed: 30340993
Adv Cancer Res. 2006;95:1-30
pubmed: 16860654
Clin Cancer Res. 2016 Jul 1;22(13):3383-97
pubmed: 26960399
Blood. 2017 Aug 24;130(8):974-981
pubmed: 28637662
N Engl J Med. 2017 Dec 28;377(26):2531-2544
pubmed: 29226797
Oncotarget. 2018 May 25;9(40):25764-25780
pubmed: 29899820
Haematologica. 2020 Jan 31;105(2):297-316
pubmed: 31753925
Blood. 2016 Jun 30;127(26):3321-30
pubmed: 27207799
N Engl J Med. 2016 Oct 6;375(14):1319-1331
pubmed: 27705267
Leukemia. 2015 Oct;29(10):2039-49
pubmed: 25975191
Leukemia. 2016 Aug;30(8):1716-24
pubmed: 27102208
Am Health Drug Benefits. 2016 Mar;9(Spec Feature):140-3
pubmed: 27668061
J Hematol Oncol. 2018 Dec 20;11(1):141
pubmed: 30572922
Blood. 2005 May 15;105(10):3939-44
pubmed: 15671442
Leukemia. 2017 Feb;31(2):382-392
pubmed: 27479184
Blood. 2005 Aug 1;106(3):1021-30
pubmed: 15827134
Nat Med. 2018 Jun;24(6):739-748
pubmed: 29808007
J Immunol. 2005 Mar 1;174(5):2591-601
pubmed: 15728465
Blood Rev. 2019 Mar;34:45-55
pubmed: 30528964
Gene Ther. 2011 May;18(5):509-16
pubmed: 21209626
Mol Immunol. 2005 May;42(7):763-72
pubmed: 15829264